CorePharma, LLC Announces the Launch of Dextroamphetamine Sulfate Tablets, USP

MIDDLESEX, N.J., June 4, 2014 /PRNewswire/ -- CorePharma, LLC ("CorePharma"), a developer, manufacturer, and marketer of targeted generic prescription pharmaceuticals, announced today that it has launched Dextroamphetamine Sulfate Tablets, USP ("Dextroamphetamine"), the generic version of Shire's Dextrostat®. Dextroamphetamine is indicated for the treatment of narcolepsy and attention deficit disorder with hyperactivity.  CorePharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) on March 7, 2014. The product is available in the 5 and 10mg strengths and has begun shipping.

The dextroamphetamine immediate release tablet market had U.S. sales of approximately $41 million according to IMS data as of April 2014.

About CorePharma
CorePharma, Middlesex, NJ, is a developer, manufacturer and marketer of targeted generic prescription pharmaceuticals across a variety of dosage forms and therapeutic categories. CorePharma operates a state-of-the-art facility, totaling 112,000 square feet of space, in Middlesex, NJ. The company actively seeks partnerships, licensing and acquisition opportunities to complement and expand its product portfolio. CorePharma is a wholly owned subsidiary of Tower Holdings, Inc. RoundTable Healthcare Partners, an operating-oriented private equity firm focused exclusively on the healthcare industry, owns a majority share of Tower Holdings.

SOURCE CorePharma, LLC